EGFR and rectal cancer: Interestingly, patients with primary tumors of the caecum derived a substantial disadvantage with anti-EGFR therapy, whereas substantial benefit was seen in patients with rectal cancers and—to a lesser extent —in patients with sigmoid primaries and rather neutral effects were seen in between.